StudyRareStudyRare

Legius syndrome

Log in to star

Last updated Nov 15, 2026

Log in to add personal notes on this page.

A 4-year-old boy has nine café-au-lait macules over 5 mm on both sides of his trunk and freckling in both axillae. His development is normal apart from a speech delay. His mother, age 35, has the same macules and freckling but no neurofibromas, and her slit-lamp exam shows no Lisch nodules.

AD; SPRED1 (Sprouty-related, EVH1 domain-containing protein 1, 15q14, a negative regulator of RAS-MAPK signaling); loss of function.

  • Many probands have an affected parent; in one clinical cohort, 6 of 23 probands had a de novo variant
  • Sequence analysis detects about 89% of pathogenic variants and deletion/duplication analysis about 10%
  • Estimated prevalence 1 in 46,000 to 1 in 75,000, against 1 in 2,000 to 1 in 3,000 for NF1
  • A RASopathy, not a form of neurofibromatosis; the name was chosen to keep the two apart in counseling

SPRED1 protein is a brake on RAS-MAPK signaling, the same pathway that neurofibromin restrains. It blocks activation of RAF1 protein kinase, and it binds neurofibromin and brings it to the plasma membrane, where neurofibromin switches RAS off. Pathogenic variants leave SPRED1 unable to perform that inhibition, so RAF-MEK-ERK signaling runs with less restraint, as it does in NF1. That shared defect explains the shared pigmentary findings.

The variants cause loss of function, and a café-au-lait macule needs both copies lost: melanocytes from a macule carried the germline SPRED1 variant plus an acquired variant in the other allele, the same two-hit pattern seen in NF1.

Why Legius syndrome is milder than the other RASopathies is not settled. The related SPRED proteins overlap in function and may compensate for SPRED1 loss in some tissues. No clinically useful genotype-phenotype correlation is known.

  • Multiple café-au-lait macules in almost everyone; the count rises through infancy, as in NF1
  • Axillary or inguinal freckling in some
  • Macrocephaly, absolute or relative (frequency varies widely between cohorts)
  • Learning disability, ADHD, and speech-predominant developmental delay; cognition is likely less affected than in NF1
  • Subcutaneous lipomas in some adults
  • Absent: neurofibromas, optic pathway glioma, the distinctive NF1 bone lesions, and Lisch nodules (one family with two affected siblings is the reported exception)
  • No NF1 tumor risk: only single tumor reports, and a 2022 review of cancer in the RASopathies concluded that tumor surveillance is not recommended
  • 2021 consensus criteria (Legius et al., Genet Med): six or more café-au-lait macules, bilaterally distributed, with no NF1 criterion other than axillary or inguinal freckling, AND a heterozygous pathogenic SPRED1 variant at a variant allele fraction of 50% in apparently normal tissue such as blood. A child of a parent who meets these criteria needs only one. Fewer than six macules does not exclude the diagnosis.
  • The diagnosis is molecular. About half of people with Legius syndrome meet the 1988 NIH clinical criteria for NF1, and a young child often cannot be sorted by examination alone, because neurofibromas and Lisch nodules usually appear later in childhood or adolescence.
  • Why it matters: in one large laboratory cohort, 1.9% of people with a clinical diagnosis of NF1 by the NIH criteria had Legius syndrome. Among 94 probands with familial café-au-lait macules, with or without freckling, and no other NF1 feature, 19% had a SPRED1 variant and 73% an NF1 variant. In 71 people aged 0 to 20 years with six or more macules and no nonpigmentary feature, 66% had an NF1 variant, 8.5% a SPRED1 variant, and 25% neither.
  • Testing strategy: in a child with pigmentary findings only, test NF1 and SPRED1 together (sequencing plus deletion/duplication analysis, usually on a RASopathy panel) rather than NF1 alone. A negative comprehensive NF1 analysis that includes RNA testing lowers the chance of NF1 in a child with six or more macules from about two in three to about one in nine.
  • Examine both parents: an adult parent with café-au-lait macules and freckling but no neurofibromas or Lisch nodules favors Legius syndrome
  • Lisch nodules on slit-lamp exam, or choroidal abnormalities on optical coherence tomography or near-infrared imaging, point to NF1
  • A SPRED1 variant of uncertain significance neither establishes nor excludes the diagnosis
  • Other causes of multiple café-au-lait macules: neurofibromatosis type 1, constitutional mismatch repair deficiency (suspect it when siblings are affected and parents are not), Noonan syndrome with multiple lentigines, McCune-Albright syndrome, and heterozygous LZTR1 loss-of-function variants
  • No consensus management guideline exists; recommendations come from GeneReviews author experience
  • No tumor surveillance: a confirmed diagnosis spares the family the NF1 schedule of eye exams for optic pathway glioma and early breast cancer screening
  • At each visit: development and school needs, ADHD screening, skin exam for pigmentary lesions and lipomas, scoliosis check (Adams forward bend test), and new seizures; hearing evaluation as needed
  • Early intervention, an individualized education plan, and ADHD treatment as needed
  • Genetic counseling: autosomal dominant, 50% risk to each child. If neither parent carries the variant in blood, recurrence in siblings is about 1% because of possible gonadal mosaicism. Prenatal and preimplantation testing are possible once the variant is known.

SPRED1 spreads the spots, not the tumors: café-au-lait macules spread over both sides of the body, as in NF1, but no neurofibromas or gliomas grow.

Reference Links